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Ferumoxytol-enhanced magnetic resonance
imaging methodology and normal values
at 1.5 and 3T
Colin G. Stirrat1*, Shirjel R. Alam1, Thomas J. MacGillivray2,3, Calum D. Gray2,3, Rachael Forsythe1, Marc R. Dweck1,
John R. Payne4, Sanjay K. Prasad5, Mark C. Petrie4, Roy S. Gardner4, Saeed Mirsadraee2, Peter A. Henriksen1,
David E. Newby1,2 and Scott I. K. Semple1,2
Abstract
Background: Ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced magnetic resonance imaging
(MRI) can detect tissue-resident macrophage activity and identify cellular inflammation. Clinical studies using this
technique are now emerging. We aimed to report a range of normal R2* values at 1.5 and 3 T in the myocardium
and other tissues following ferumoxytol administration, outline the methodology used and suggest solutions to
commonly encountered analysis problems.
Methods: Twenty volunteers were recruited: 10 imaged each at 1.5 T and 3 T. T2* and late gadolinium enhanced
(LGE) MRI was conducted at baseline with further T2* imaging conducted approximately 24 h after USPIO infusion
(ferumoxytol, 4 mg/kg). Regions of interest were selected in the myocardium and compared to other tissues.
Results: Following administration, USPIO was detected by changes in R2* from baseline (1/T2*) at 24 h in myocardium,
skeletal muscle, kidney, liver, spleen and blood at 1.5 T, and myocardium, kidney, liver, spleen, blood and bone at 3 T
(p < 0.05 for all). Myocardial changes in R2* due to USPIO were 26.5 ± 7.3 s-1 at 1.5 T, and 37.2 ± 9.6 s-1 at 3 T (p < 0.0001
for both). Tissues showing greatest ferumoxytol enhancement were the reticuloendothelial system: the liver, spleen and
bone marrow (216.3 ± 32.6 s-1, 336.3 ± 60.3 s-1, 69.9 ± 79.9 s-1; p < 0.0001, p < 0.0001, p = ns respectively at 1.5 T, and
275.6 ± 69.9 s-1, 463.9 ± 136.7 s-1, 417.9 ± 370.3 s-1; p < 0.0001, p < 0.0001, p < 0.01 respectively at 3 T).
Conclusion: Ferumoxytol-enhanced MRI is feasible at both 1.5 T and 3 T. Careful data selection and dose administration,
along with refinements to echo-time acquisition, post-processing and analysis techniques are essential to ensure reliable
and robust quantification of tissue enhancement.
Trial registration: ClinicalTrials.gov Identifier - NCT02319278. Registered 03.12.2014.
Keywords: Cardiac, MRI, Inflammation, USPIO
Background
Iron oxide nanoparticles are a class of magnetic reson-
ance imaging (MRI) contrast agents that are generating
interest as a method of detecting tissue inflammation.
Historically, these nanoparticles were initially used for
gastrointestinal, reticuloendothelial system and lymph
node imaging [1–3], and subsequently in hepatic and
cardiac imaging [4–7]. Recently however, it is in their
use as an MRI contrast agent for detecting tissue-
resident macrophages that clinical applications are now
emerging [8–15].
T2* MRI has been successfully used for over a decade
in diagnosing and grading severity of iron accumulation
in transfusion-dependent thalassaemia major, and has
been instrumental in guiding therapy that improves
prognosis, and allows serial disease monitoring [16, 17].
T2* MRI in the assessment of iron accumulation is easily
quantifiable, well validated, highly reproducible, clinically
robust, and is achievable in a single breath hold [18–22].
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Ultrasmall superparamagnetic particles of iron oxide
(USPIO) consist of an iron oxide core surrounded by a
carbohydrate or polymer coating. These particles can ex-
travasate through damaged capillaries, where they are
engulfed and concentrated by tissue-resident macrophages
[23]. Gradient echo T2*-weighted (T2*W) sequences are
highly sensitive to magnetic field inhomogeneities such as
susceptibility artifacts due to the presence of iron, includ-
ing USPIO. Accumulation of USPIOs in macrophages can
be quantified and visualized using T2*W MRI [8, 9] and
calculation of, and observing the reduction in, T2*
relaxation time due to the presence of iron. Thus USPIO-
enhanced MRI can detect tissue-resident macrophage ac-
tivity and identify localized cellular inflammation within
tissues.
In this present study we aimed to observe and quantify
the distribution ferumoxytol enhancement following
intravenous administration at 1.5 and 3 T MRI and es-
tablish a range of normal values for healthy myocardium
and other tissue. We also aimed to develop our method-
ology and describe commonly encountered problems in
T2* image analysis of USPIO.
Methods
This was an open-label observational multi-centre
cohort study using human volunteers recruited as part
of a larger trial, recruiting patients with cardiac inflam-
mation. The study was performed in accordance with
the declaration of Helsinki, the approval of the Scotland
A research ethics committee, and the written informed
consent of all participants.
Subjects
Participants were aged over 18 years of age. Exclusion
criteria were contraindication to MRI or ferumoxytol
infusion, any systemic inflammatory comorbidity (eg
rheumatoid arthritis), renal failure (estimated glomerular
filtration rate <30 mL/min), pregnancy, breastfeeding
and women of child-bearing age not ensuring reliable
contraception.
Magnetic resonance imaging
MRI was performed using 3 T and 1.5 T scanners (Magne-
tom Verio and Avanto respectively, Siemens Healthcare
GmbH, Erlangen, Germany), with dedicated cardiac array
coils. All images were acquired using electrocardiogram-
gated breath-hold imaging. Routine steady state free preces-
sion (TrueFISP) sequences were used to acquire long-axis
and short-axis images of the heart. Standard cardiac slice
widths (6-mm width with 4-mm gap) and 8 echo times
(2.1–17.1 ms range) with matrix size of 256 × 115 were ac-
quired in order to generate T2* maps. The in-plane reso-
lution differed as required for larger or smaller subjects;
generally, a field of view of 400 × 300 mm was used with an
in-plane resolution of 2.6 × 1.6 mm. T2* relaxation maps
were generated before and approximately 24 h after admin-
istration of USPIO.
Immediately after the baseline T2* and SSFP cine im-
aging, breath-held inversion enhancement images were
acquired following an intravenous administration of gado-
linium contrast medium (0.1 and 0.15 mmol/kg at 3 T and
1.5 T respectively; Gadovist, Bayer Plc, Germany).
Fig. 1 MRI protocol
Table 1 Participant characteristics
1.5 T 3 T
Number 9 10
Male;Female 3:6 4:6
Age (years) 52 [45.5–61.5] 50 [45.25–53]
Body-mass Index (kg/m2) 22.9 [20.1–26.9] 25.9 [22.5–29.4]
Ejection Fraction (%) 63.6 ± 4.9 61.1 ± 4.1
N (%), mean ± SD, or median [interquartile range]
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Optimal inversion time (TI) was determined on a slice-by-
slice basis using standard late-enhancement TI-scout
protocols. The inversion-recovery late-enhancement
short-axis slices were acquired using similar slice positions
to the myocardial T2* imaging. The T2* acquisitions also
included imaging of the liver, spleen and spine to allow
quantification of USPIO accumulation within organs of
the reticuloendothelial system.
USPIO
Intravenous infusion of USPIO (ferumoxytol, 4 mg/kg;
Rienso®, Takeda Italia, Italy) was performed immediately
following the baseline magnetic resonance scan over at
least 15-min using a concentration of 2–8 mg/mL, di-
luted in 0.9 % saline or 5 % dextrose. Hemodynamic
monitoring was conducted throughout.
Study protocol
Volunteers received 2 MRI scans approximately 24 h
apart (Fig. 1).
Image analysis
All T2*-weighted multi-gradient-echo images for each pa-
tient were analyzed using Circle CVI software (Circle
CVI42, Canada). Regions of interest (ROI) were drawn in
the heart using standard cardiac segmentation [24], and
panmyocardial values averaged using segments 1–16. Fur-
ther ROI were drawn in skeletal muscle, kidney, liver,
spleen, blood pool (from LV cavity) and bone marrow.
An experimentally determined threshold used in previ-
ous work [8] for the coefficient of determination (r2 >
0.85) was used to exclude data that did not have an ac-
ceptable exponential decay when signal intensity (SI) was
plotted against echo time. The inverse of the mean T2*
(R2*) for each ROI was then calculated to assess the up-
take of USPIO, where the higher the value, the greater the
USPIO accumulation.
Late gadolinium enhancement (LGE), ventricular vol-
ume and functional analyses were performed using Circle
CVI software (Circle CVI42, Calgary, Canada). T2* data
were collected immediately prior to USPIO administra-
tion. USPIO-enhanced T2* data were collected 24–25 h
following ferumoxytol administration.
Statistical analysis
All statistical analysis was performed with GraphPad
Prism, version 6 (GraphPad Software, San Diego, CA).
To assess uptake of USPIO in tissues following single
administration, R2* increase from pre to 24 h following
USPIO were compared using repeated measures one-
way ANOVA. Statistical significance was defined as two-
sided p < 0.05.
Results
Twenty volunteer patients were recruited in total (10 at
1.5 T, 10 at 3 T). Forty MRI scans and 20 infusions of
ferumoxytol were completed over the course of the
study. Data from one participant at 1.5 T has been re-
moved due to the presence of LGE, (which was included
Table 2 Normal values
1.5 T Pre-USPIO
R2*(s-1)
1.5 T Post-USPIO
R2*(s-1)
1.5 T Change
R2*(s-1)
3 T Pre-USPIO
R2*(s-1)
3 T Post-USPIO
R2*(s-1)
1.5 T Change
R2*(s-1)
Panmyocardial average 33.5 ± 5.4 60.5 ± 7.2 26.5 ± 7.3 46.9 ± 4.1 84.2 ± 12.4 37.2 ± 9.6
Skeletal muscle 34.7 ± 4.2 44.9 ± 4.7 10.2 ± 5.8 55.5 ± 17.1 59.8 ± 6.6 4.3 ± 16.3
Kidney 16.6 ± 2.0 81.2 ± 15.2 64.6 ± 16.1 43.5 ± 39.1 115.2 ± 28.1 71.8 ± 48.8
Liver 36.0 ± 7.2 252.3 ± 34.3 216.3 ± 32.6 65.3 ± 21.2 340.9 ± 57.8 275.6 ± 69.9
Spleen 22.0 ± 7.7 358.3 ± 59.5 336.3 ± 60.3 51.2 ± 21.1 515.1 ± 137.4 463.9 ± 136.7
Blood 11.3 ± 4.1 96.0 ± 26.6 84.7 ± 27.2 18.8 ± 5.3 91.5 ± 20.9 72.6 ± 18.3
Bone 84.4 ± 29.2 154.3 ± 62.0 69.9 ± 79.9 330 ± 168.7 747.9 ± 277.8 417.9 ± 370.3
Mean ± SD
Fig. 2 Myocardial R2* pre- and post-USPIO administration at 1.5 and
3 T. Following administration, USPIO was detected by an increase in
R2* at 24 h in the myocardium at both 1.5 and 3 T.
(**** = p < 0.0001, ** = p < 0.01)
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in the cardiac MR protocol so that we could exclude vol-
unteers with any detectable cardiac MR abnormalities
according to standard cardiac MR protocols). All other
volunteers that were included had structurally normal
hearts. One participant was prescribed antihypertensive
medication but had a normal cardiac MR study and was
normotensive so the data was retained for analysis. Ad-
ministration of ferumoxytol was well tolerated with no
adverse reactions reported during or immediately after
administration in any of the participants.
Participants were predominantly middle aged, with
greater numbers of women in both groups (Table 1).
There were no differences between 1.5 T and 3 T groups
in BMI or ejection fraction at baseline.
A summary of results is shown in Table 2. At baseline,
panmyocardial R2* values were greater at 3 T than 1.5 T
(46.9 ± 4.1 versus 33.5 ± 5.4 s-1, Fig. 2, p < 0.01) as ex-
pected. Baseline R2* values were also greater at 3 T in
bone (P < 0.0001) but no baseline differences were seen
between magnetic field strength in all other tissues (Fig. 3,
p > 0.05 for all). USPIO increased panmyocardial R2*
values at 24 h in both 1.5 T and 3 T scanners (p < 0.0001
for both). Post-USPIO panmyocardial R2* values were
again greater at 3 T than 1.5 T, as expected (84.2 ± 12.4
Fig. 3 Tissue R2* pre- and post-USPIO administration at 1.5 and 3 T. Following administration, USPIO was detected by an increase in R2*, 24 h
after administration in skeletal muscle, kidney, liver, spleen and blood at 1.5 T, and kidney, liver, spleen, blood and bone at 3 T. (**** = p < 0.0001,
*** = p < 0.001, ** = p < 0.01, * = p < 0.05)
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versus 60.5 ± 7.2 s-1, p < 0.0001). Panmyocardial change in
R2* between baseline and 24 h post USPIO at 1.5 T was
26.5 ± 7.3 s-1 and at 3 T was 37.2 ± 9.6 s-1 (p < 0.0001 for
both). Detectable increases in R2* were also observed at
24 h post-USPIO in skeletal muscle, kidney, liver, spleen
and blood at 1.5 T, and kidney, liver, spleen, blood and
bone at 3 T. (Fig. 3, p < 0.05 for all). BMI correlated with
the panmyocardial R2* changes due to USPIO contrast
(Fig. 4; r = 0.72, p < 0.001).
Discussion
For the first time, we report a range of normal T2*
values in the healthy human heart and other tissues 24 h
after ferumoxytol administration at 1.5 and 3 T. We also
report problems, solutions and guidance in ferumoxytol-
enhanced T2* image analysis.
Following administration, USPIO is detectable by T2*
imaging in the myocardium and other tissues at both 1.5
and 3 T. Tissues with small increases in R2* (less than
the blood pool) are likely to represent detection of
USPIOs within the intravascular space and include skel-
etal muscle (at 1.5 T only), myocardium and kidney. In
contrast, R2* changes that are greater than the blood
pool must be due to accumulation of USPIO, either
through iron storage, uptake by macrophages or other
phagocytes, or sequestered within tissue interstitium. In
the absence of tissue biopsies, we cannot be certain, but
as the most pronounced R2* changes were seen in the
spleen, liver and bone marrow - organs of the reticulo-
endothelial system - it would appear likely that USPIO is
incorporated quickly into tissue-resident phagocytes and
macrophages.
Detection of USPIO enhancement in skeletal muscle at
1.5 T but not 3 T is due to generally noisier data seen
across all tissues at 3 T. Due to wider data confidence inter-
vals, a larger sample size would be required to detected the
same mean change in R2*. The variation in data at 3 T is
partly artifact in the images, but also because of the lower
values at 3 T (USPIO has a faster T2* decay time at 3 T).
With the same sampling echo times, there are fewer data
points to construct the decay curve at 3 T than 1.5 T so
our error in estimation also increases.
We chose 24 h post USPIO to re-image participants as
myocardial signal attenuation at 24 h has shown to be
optimal in the myocardium compared to later time
points [8, 9]. In view of this, scanning appointments
were generally separated by 25 h, and in practice, this re-
gime worked well for both participants and MRI plan-
ning. According to previous work [8], we chose a
weight-adjusted USPIO dose of 4 mg Fe/kg body weight.
However acknowledging that the distribution of USPIO
following administration is predominantly in the organs
of the reticuloendothelial system and blood pool, this
may not be the optimum administration strategy as
blood volume does not increase linearly with weight. We
found a correlation between BMI and myocardial R2*
change, probably due to increased blood pool USPIO
concentration in those with higher BMI. We therefore
suggest that a fixed dose approach may also be appropri-
ate depending on the application.
Artifacts were commonly encountered with USPIO-
enhanced T2* imaging and made data analysis challenging.
Post contrast artifacts at the blood-pool to myocardial
interface were commonly seen and needed careful exclu-
sion when selecting myocardial ROI. (Fig. 5A) This limited
the assessment of USPIO accumulation at the endocar-
dium. Similarly, blooming artifacts from nearby organs with
high iron or blood pool USPIO content, such as lung and
liver, commonly created signal deficits within the myocar-
dium. In this situation, examination of T2* decay curves
and excluding echo times influenced by artifact aided T2*
decay curve fitting (Fig. 5).
The advantage of MRI mapping techniques is that visual
assessment and objective quantification can be made using
the same image, and these are now entering clinical prac-
tice. It seems likely that if UPSIO-enhanced MRI is adopted
into clinical practice to detect tissue inflammation, T2*
mapping would be used for image interpretation. However
based on our experiences, we would recommend caution in
interpreting maps alone. Signal attenuation seen on the T2*
map may be interpreted as tissue USPIO accumulation, but
may be due to blooming artifact from nearby susceptibility
effects, and close examination of the T2* decay curve, and
individual echoes if possible is suggested in order to distin-
guish accurately between tissue USPIO accumulation and
artifact. In theory, setting an r2 threshold as we did helps to
exclude areas grossly affected by artifact. In practice how-
ever, regions with a seemingly acceptable R2 may still be in-
fluenced by artifact (Fig. 5). Manual exclusion of later
echoes (influenced by artifact) from the curve may result in
an improvement in R2 (a measure of how well the data
Fig. 4 Body-mass Index vs Panmyocardial R2* change at 1.5 and
3 T. Body-mass index correlates with panmyocardial R2* change
pre- and post-USPIO
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Fig. 5 (See legend on next page.)
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points fit the curve), however there is the danger that redu-
cing the number of fitting points will in fact reduce the
overall sampling accuracy. Clearly, automated software
capable of detecting and excluding artifact would be
advantageous. This could be achieved by excluding, or ap-
plying less weight, to later echo times especially data points
at a large distance from the initial decay curve trajectory
[25, 26]. It should be noted that like all other MRI se-
quences, poor data quality heavily influenced by breathing
or movement artifact is generally non-interpretable and
post processing using automated T2* decay curve fitting
software is not likely to provide a remedy.
Echo times in this study were specific for cardiac im-
aging and were selected appropriately. Therefore they
were not optimal for imaging tissues with T2* values
substantially higher or lower than myocardium. Native
blood pool and post USPIO bone marrow (Fig. 6) pro-
vide examples of low and high T2* values respectively
that we had difficulty accurately fitting a T2* decay
curve. With high T2* values, only a short part of the
decay curve is plotted over the echo sampling time
period, and often the signal has not decayed sufficiently
for an accurate decay curve to be plotted. In contrast,
regions with particularly short T2* decay times have
decayed to a level expected from background noise be-
fore sufficient data sampling has been made. Therefore
fitting a decay curve from a small number (2–4) of echo
times is clearly difficult, and often too much emphasis is
(See figure on previous page.)
Fig. 5 Inferior Blooming artifact. Example illustrating the challenge in assessing whether the inferior myocardial signal attenuation seen arrowed
on the T2* colourmap (a, scale 0-60 ms) is true or caused by artifact. Drawing a region of interest (b) and examining the decay curve (c) along
with visualising individual echos (d1-8) helps determine that this is a ‘blooming artifact’ from outside the heart is seen to influence echos 4-8.
These can be manually removed, forming a new decay curve (e) with improvement in curve fitting (R2 value), although with fewer fitting points
Fig. 6 Example of high and low T2* values. Regions of Interest with excessively low or high T2* value (pre-contrast blood pool, a, and post
USPIO bone marrow, b, respectively) can often be difficult to generate an accurate T2* decay curve. Imaging with tissue-spcific echo times will
help generate more accurate T2* decay curves
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placed upon data decayed to the baseline level of back-
ground noise in order to generate a decay curve. Allow-
ances can be made for background noise but are of
limited value in this instance. We strongly advise apply-
ing tissue-specific echo times tailored to the expected
T2* value in order to achieve the most accurate decay
curves possible.
Limitations
There are some limitations that should be taken into ac-
count when interpreting these data. First, this study has
small numbers and a larger cohort of participants should
be studied to further validate these normal values. Fur-
thermore, due to geographical reasons, it was not feas-
ible to scan the same participants at both centres so
comparison cohorts at 1.5 T and 3 T were different. Des-
pite this, both were healthy volunteers groups and dis-
played no differences at baseline so we do not feel this
has impacted on the results. Finally, due to problems in
interpreting high and low T2* values as mentioned
above, we recommend caution in interpreting some high
non-cardiac R2* values; especially in the organs of the
reticuloendothelial system at 3 T. In these organs, the
spread of R2* data above the median value appears wide.
This is possibly caused by artifact and most evident at
3 T, and may additionally explain why these regions have
disproportionally high R2* values.
Conclusion
We have shown that ferumoxytol-enhanced MRI is feasible
at both 1.5 T and 3 T, and suggest a range of expected nor-
mal values post-ferumoxytol in a range of tissues. Refine-
ments of dose administration, optimization of acquired
echo-times, careful image analysis, and development of
post-processing and analysis software capable of excluding
common artifacts, are essential to ensure reliable and ro-
bust quantification of tissue enhancement.
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